Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The transcription factor NR4A3 controls CD103+ dendritic cell migration
Kiwon Park, … , Mitchell Kronenberg, Catherine C. Hedrick
Kiwon Park, … , Mitchell Kronenberg, Catherine C. Hedrick
Published November 7, 2016
Citation Information: J Clin Invest. 2016;126(12):4603-4615. https://doi.org/10.1172/JCI87081.
View: Text | PDF
Research Article Immunology

The transcription factor NR4A3 controls CD103+ dendritic cell migration

  • Text
  • PDF
Abstract

The transcription factor NR4A3 (also known as NOR-1) is a member of the Nr4a family of nuclear receptors and is expressed in myeloid and lymphoid cells. Here, we have shown that Nr4a3 is essential for the migration of CD103+ dendritic cells (DCs) to lymph nodes (LNs). Nr4a3-deficient mice had very few CD103+ migratory DCs (mDCs) present in LNs, and mixed-chimera studies revealed that this migratory defect was cell intrinsic. We further found that CD103+ DCs from Nr4a3-deficient mice displayed a marked loss of surface expression of the chemokine CCR7. This defect in CCR7 expression was confined to CD103+ DCs, as CCR7 expression on T lymphocytes was unaffected. Moreover, CCR7 was not induced on CD103+ DCs from Nr4a3-deficient mice in response to either administration of the TLR7 agonist R848 or infection with Citrobacter rodentium in vivo. The transcription factor FOXO1 has been shown to regulate CCR7 expression. We found that FOXO1 protein was reduced in Nr4a3-deficient DCs through an AKT-dependent mechanism. Further, we found a requirement for NR4A3 in the maintenance of homeostatic mitochondrial function in CD103+ DCs, although this is likely independent of the NR4A3/FOXO1/CCR7 axis in the regulation of DC migration. Thus, NR4A3 plays an important role in the regulation of CD103+ mDCs by regulating CCR7-dependent cell migration.

Authors

Kiwon Park, Zbigniew Mikulski, Goo-Young Seo, Aleksander Y. Andreyev, Paola Marcovecchio, Amy Blatchley, Mitchell Kronenberg, Catherine C. Hedrick

×

Figure 2

mDC defect in Nr4a3-deficient mice is hematopoiesis derived and cell intrinsic.

Options: View larger image (or click on image) Download as PowerPoint
mDC defect in Nr4a3-deficient mice is hematopoiesis derived and cell int...
(A) BM transplantation. BM from CD45.2 Nr4a3+/+ or CD45.2 Nr4a3–/– mice was transplanted into sublethally irradiated CD45.1 recipient mice. After 8 weeks of reconstitution, mDCs and MLN-resident DCs (rDCs) were analyzed by flow cytometry. Results represent 1 of 2 independent experiments (n = 4 mice per group). (B) Mixed BM chimeras. BM hematopoietic stem cell progenitor cells from CD45.2 Nr4a3+/+ or CD45.2 Nr4a3–/– mice were mixed 1:1 with CD45.1 cells to make CD45.2 Nr4a3+/+ plus CD45.1 and CD45.2 Nr4a3+/+ plus CD45.1 chimeras. 1:1 BM precursor mixtures were transferred into sublethally irradiated CD45.1/2 heterozygous mice. After 10 days, the mice were sacrificed for analysis. DC populations were analyzed in colon and MLNs. BM reconstitution was assessed in blood samples. The percentage of CD45.2 cells was calculated from total donor cells that included CD45.2 and CD45.1 cells. Results represent 1 of 2 independent experiments (n = 3–4 mice per group). *P < 0.05 and ** P < 0.01, by an unpaired 2-tailed Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts